Phoenixville, PA, United States of America

Juan Luengo

This inventor holds 15 USPTO granted patents and 8 published patent applications and 3 EPO patents, primarily in Cancer Therapeutics. Top assignees: Prelude Therapeutics Incorporated, Quanta Therapeutics, Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Juan Luengo. Retrieved from https://idiyas.com/inventor/juan-luengo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 8)

% Patents Active = 86.7

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

11 out of 19

Prelude Therapeutics Incorporated

patents

4 out of 5

Quanta Therapeutics, Inc.

patents

Years Active: 2020-2026

Loading Chart...

Areas of Expertise:

KRAS Modulators

PRMT5 Inhibitors

Pyrimidine Based Modulators

Spiro-Sulfonamide Derivatives

Myeloid Cell Leukemia-1

Selective Inhibitors

Protein Arginine Methyltransferase

Cancer Treatment

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624052 - KRAS modulators and uses thereof (2026-05-12),

2. 12459950 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-11-04),

3. 12440506 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2025-10-14),

4. 12421254 - KRAS modulators and uses thereof (2025-09-23),

5. 12145947 - Pyrimidine based modulators and uses thereof (2024-11-19),

6. 11912723 - KRAS modulators and uses thereof (2024-02-27),

7. 11524962 - Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) (2022-12-13),

8. 11254683 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-02-22),

9. 11220524 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-01-11),

10. 11214574 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2022-01-04),

11. 11208416 - Selective inhibitors of protein arginine methytransterase 5 (PRMT5) (2021-12-28),

12. 11130769 - Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein (2021-09-28),

13. 11078205 - Selective inhibitors of protein arginine methlytransferase 5 (PRMT5) (2021-08-03),

14. 10711007 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2020-07-14),

15. 10570140 - Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) (2020-02-25),

Title: Juan Luengo: Pioneering Innovations in Phoenixville

Introduction:

Juan Luengo, a visionary inventor based in Phoenixville, PA, is a driving force in the world of technology and innovation. With a passion for pushing boundaries and a commitment to excellence, he continues to inspire the next generation of inventors.

Latest Patents:

Among his impressive portfolio of 10 patents, two recent groundbreaking inventions stand out. The first involves KRAS modulators, compounds that are instrumental in modulating KRAS GD12 and other G12 mutants. The second patent revolves around substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5). These patents showcase Juan Luengo's expertise and groundbreaking contributions to the field of biotechnology.

Career Highlights:

Juan Luengo has made significant contributions to companies such as Prelude Therapeutics Incorporated and Quanta Therapeutics, Inc. His innovative ideas and relentless pursuit of excellence have helped these companies drive forward in the competitive landscape of technology and biotechnology.

Collaborations:

Throughout his career, Juan Luengo has had the privilege of collaborating with esteemed professionals in the industry. Notable coworkers such as Hong Lin and Rupa S Shetty have been integral to the success of many projects led by Juan Luengo. These collaborations have resulted in groundbreaking inventions and patents that have shaped the future of technology.

Conclusion:

In conclusion, Juan Luengo's remarkable journey as an inventor and innovator has left an indelible mark on the world of technology. His passion for innovation, coupled with his relentless pursuit of excellence, continues to inspire and shape the future of technology for generations to come.

Profile summary based on public USPTO records.